Case Report: Eosinophilic Bronchiolitis With Eosinophil ETosis in Mucus Plugs Successfully Treated With Benralizumab.

Charcot-Leyden crystal ETosis benralizumab eosinophil eosinophilic bronchiolitis mucus plug

Journal

Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923

Informations de publication

Date de publication:
2021
Historique:
received: 01 12 2021
accepted: 27 12 2021
entrez: 31 1 2022
pubmed: 1 2 2022
medline: 1 2 2022
Statut: epublish

Résumé

Eosinophilic bronchiolitis is a rare allergic disorder caused by eosinophilic inflammation in the bronchioles of the lungs. An effective treatment strategy is needed in cases resistant to steroids. However, its pathophysiology remains unclear owing to the limited number of cases. We herein present the case of a 31-year-old man who experienced eosinophilic bronchiolitis with eosinophil ETosis (EETosis) in the mucus plugs. The patient was diagnosed with asthma. His respiratory symptoms worsened with eosinophilia when treated with the standard asthma regimen, including inhaled corticosteroids, long-acting β2-agonist, long-acting muscarinic antagonist, and leukotriene receptor antagonist. Chest computed tomography revealed bronchial wall thickening and centrilobular nodules in the lower lobes of both lungs. Bronchoscopy showed obstruction of the subsegmental bronchus with mucus plugs. Histological analysis demonstrated abundant eosinophils in the mucus plugs. Cytolytic eosinophils together with Charcot-Leyden crystal formations and deposition of major basic proteins were also observed, indicating the occurrence of EETosis. Introduction of benralizumab, an anti-interleukin-5 receptor α antibody, successfully controlled the patient's condition and reduced the amount of systemic corticosteroids administered. Our findings confirm that this antibody strongly decreases airway eosinophils in patients with severe asthma. Thus, benralizumab might be an optimal therapeutic agent for the treatment of mucus plug-forming and/or EETosis-occurring eosinophilic lung diseases, including eosinophilic bronchiolitis.

Identifiants

pubmed: 35095536
doi: 10.3389/fphar.2021.826790
pii: 826790
pmc: PMC8794752
doi:

Types de publication

Case Reports

Langues

eng

Pagination

826790

Informations de copyright

Copyright © 2022 Sasaki, Miyata, Irie, Kuwata, Kouzaki, Ueki and Kawana.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The handling editor declared a past co-authorship with one of the authors SU.

Références

Eur Respir J. 2013 May;41(5):1012-3
pubmed: 23633610
Allergy. 2020 Dec;75(12):3087-3099
pubmed: 33040364
N Engl J Med. 2017 Jun 22;376(25):2448-2458
pubmed: 28530840
Eur Rev Med Pharmacol Sci. 2015;19(14):2634-40
pubmed: 26221894
J Asthma Allergy. 2021 Nov 30;14:1441-1452
pubmed: 34880630
N Engl J Med. 2014 Sep 25;371(13):1189-97
pubmed: 25199060
Lancet. 2016 Oct 29;388(10056):2115-2127
pubmed: 27609408
Allergy. 2019 Nov;74(11):2181-2190
pubmed: 31095758
Lancet. 2016 Oct 29;388(10056):2128-2141
pubmed: 27609406
J Allergy Clin Immunol. 2013 Nov;132(5):1086-1096.e5
pubmed: 23866823
Eur Respir J. 2021 Jul 21;:
pubmed: 34289975
Asia Pac Allergy. 2021 Jul 13;11(3):e29
pubmed: 34386405
Respirol Case Rep. 2021 Jul 20;9(8):e00810
pubmed: 34306708
Am J Respir Crit Care Med. 2003 Jan 15;167(2):199-204
pubmed: 12406833
J Allergy Clin Immunol Pract. 2020 Mar;8(3):1159-1161.e1
pubmed: 31678294
Allergol Int. 2018 Jul;67(3):414-416
pubmed: 29242145
J Clin Invest. 2018 Mar 1;128(3):997-1009
pubmed: 29400693
Allergol Int. 2021 Jan;70(1):19-29
pubmed: 33189567
Allergol Int. 2020 Oct;69(4):636-638
pubmed: 32247541
Asia Pac Allergy. 2021 Jul 12;11(3):e28
pubmed: 34386404
F1000Res. 2020 Jun 23;9:637
pubmed: 32864107

Auteurs

Hisashi Sasaki (H)

Division of Infectious Diseases and Respiratory Medicine, Department of Internal Medicine, National Defense Medical College, Saitama, Japan.

Jun Miyata (J)

Division of Infectious Diseases and Respiratory Medicine, Department of Internal Medicine, National Defense Medical College, Saitama, Japan.

Akiko Irie (A)

Department of Internal Medicine, Japan Self-Defense Forces Central Hospital, Tokyo, Japan.

Ayako Kuwata (A)

Department of Internal Medicine, Japan Self-Defense Forces Central Hospital, Tokyo, Japan.

Yuji Kouzaki (Y)

Department of Internal Medicine, Japan Self-Defense Forces Central Hospital, Tokyo, Japan.

Shigeharu Ueki (S)

Department of General Internal Medicine and Clinical Laboratory Medicine, Akita University Graduate School of Medicine, Akita, Japan.

Akihiko Kawana (A)

Division of Infectious Diseases and Respiratory Medicine, Department of Internal Medicine, National Defense Medical College, Saitama, Japan.

Classifications MeSH